https://www.selleckchem.com/pr....oducts/ldn193189.htm
Objective To assess the safety of ocrelizumab (OCR) shorter duration infusion in patients with MS. Methods ENSEMBLE PLUS is a randomized, double-blind substudy to the single-arm ENSEMBLE study (NCT0308581. In ENSEMBLE, patients with early stage relapsing-remitting MS received OCR 600 mg initially as two 300 mg IV infusions 2 weeks apart and subsequently as a single 3.5-hour 600 mg infusion every 24 weeks for 192 weeks. In ENSEMBLE PLUS, OCR 600 mg administered over the approved 3.5-hour infusion time (conventional duration) is compa
Like
Comment
Share
